Document:

Unassociated Document

    

    WARRANT
      AMENDMENT

    

    REFERENCE
      is hereby made to the Warrants referred to in Schedule A hereto to purchase
      an
      aggregate of 99,000 shares of the Common Stock of bioMETRX, Inc., a Delaware
      corporation (the “Company”) in the names set forth on such Schedule A (the
“Holder”) originally issued on or about November 17, 2006.

    

     

    WHEREAS
      the Company has determined that it is in its best interest to offer the warrants
      at an Exercise Price of $1.00 per share of common stock.

    

    NOW
      THEREFORE, in consideration of the agreements set forth in this agreement and
      those related to the original issuance of the Original Warrants.

    

    1. CERTAIN
      DEFINITIONS.

    

    (a)
      Except as otherwise provided in this agreement, all words and terms defined
      in
      the Original Warrants, have the same meanings in this agreement as such defined
      words and terms are given in the Original Warrants.

    

    (b)
      “Warrant” means the Original Warrants, as supplemented and amended this
      agreement and as from time to time further supplemented and
      amended.

    

    (c)
      “Amendment” means this agreement dated August 24, 2007.

    

    2. EXTENSION
      OF EXPIRATION DATE

    

    The
      Original Warrants are amended to read as follows:

    

    “The
      Warrants may be exercised at anytime at the option of the Holder
      until
      August
      24, 2011 at an exercise price of $1.00 per share of common stock.”

    

    This
      Amendment has been duly authorized and approved by all required corporate action
      by the Company and does not violate the certificate of incorporation or by-laws
      of the Company.

    
      	 	 	 
	 	bioMETRX,
              Inc.
	 
 	 
 	 
 
	
              Dated:
                August 24, 2007

            	By:  	
            
	 	
              

              Mark
                Basile

              Chief
                Executive Officer

            
	 	Title 

    

    

    ____________________

    Lorraine
      Yarde

    Secretary

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    
      SCHEDULE
        A

    

    
      	NAME	 	
              WARRANTS

            	 
	Jane
              Petri	 	 	49,500	 
	Joseph
              Panico	 	 	49,500	 
	
               TOTAL 

            	 	 	99,000WARRANT
        AMENDMENT

       

      REFERENCE
        is hereby made to the Warrants referred to in Schedule A hereto to purchase
        an
        aggregate of 125,000 shares of the Common Stock of bioMETRX, Inc., a Delaware
        corporation (the “Company”) in the names set forth on such Schedule A (the
“Holder”) originally issued on or about December 28, 2006.

      

      WHEREAS,
        the Company has determined that it is in its best interest to modify the
        Original Warrants to extend the exercise period set forth and extend the
        exercise date in the Original Warrants.

      

      NOW
        THEREFORE, in consideration of the agreements set forth in this agreement
        and
        those related to the original issuance of the Original Warrants.

      

      
        	
                1.

              	
                CERTAIN
                  DEFINITIONS.

              

      

      

      (a)
        Except as otherwise provided in this agreement, all words and terms defined
        in
        the Original Warrants, have the same meanings in this agreement as such defined
        words and terms are given in the Original Warrants.

      

      (b)
        “Warrant” means the Original Warrants, as supplemented and amended this
        agreement and as from time to time further supplemented and
        amended.

      

      (c)
        “Amendment” means this agreement dated August 24, 2007.

      

      
        	
                2.

              	
                REDUCTION
                  OF EXPIRATION PRICE

              

      

      

      The
        Original Warrants are amended to read as follows:

      

      “Exercise
        Price.
        The
        exercise price per share of the Common Stock under this Warrant shall
 be
        $1.00,
        subject to adjustment hereunder (the “Exercise
        Price”).”

      

      
        	
                3.
                  

              	
                EXTENSION
                  OF EXPIRATION DATE

              

      

      

      The
        Original Warrants are amended to read as follows:

      

      “The
        Warrants may be exercised at any time at the option of the Holder until August
        24, 

      2011
        at
        an exercise price of $1.00 per share of common stock”.

      

      
        	
                4.

              	
                EFFECT
                  OF ORIGINAL WARRANT

              

      

      

      Except
        as
        supplemented and amended by this Amendment and such conforming changes as
        necessary to reflect the modification herein, all of the provisions of the
        Warrant shall remain in full force and effect from and after the effective
        date
        of this Agreement.

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      

      This
        Amendment has been duly authorized and approved by all required corporate
        action
        by the Company and does not violate the certificate of incorporation or by-laws
        of the Company.

       

      
        	 	 	 
	 	bioMETRX,
                Inc.
	 
 	 
 	 
 
	 	By:  	 
	 	
                
Mark
                Basile
	 	Chief
                Executive Officer
	
                Dated: August 24, 2007

              	 
	
                 

                 

              	 
	
                
J.
                Richard Iler	 
	Secretary	 

        
          
             

             

          

          
             

            
              

            

          

          
             

          

        

      

       

      
        	
                SCHEDULE
                  A

              
	 	 
	 	 
	
                NAME

              	
                WARRANTS

              
	 	 
	 	 
	
                Jane
                  Petri

              	
                62,500

              
	 	 
	
                Joseph
                  Panico

              	
                62,500REGISTRATION
      RIGHTS AGREEMENT

    

    This
      Registration Rights Agreement (this “Agreement”)
      is
      made and entered into as of August ___, 2007, by and between bioMETRX, Inc.,
      a
      Delaware corporation (the “Company”), and Jane Petri.

    

    WHEREAS,
      the Purchaser has made loans to the Company from time to time; and 

    

    WHEREAS,
      the Purchaser has agreed to lend the Company an additional $87,500 thereby
      bringing the total amount due by the Company to the Purchaser to $400,000;
      and

    

    WHEREAS,
      the Company concurrently herewith has issued the Purchaser a new Convertible
      Note (“Note”) in the aggregate principal amount of $400,000 which supercedes and
      replaces all outstanding Promissory Notes issued to Purchaser; and 

    

    WHEREAS,
      as condition for the Purchaser providing the Company with the additional $87,500
      the Company has agreed to register under certain circumstance the shares
      underlying the Convertible Note and any all shares underlying Warrants currently
      owned by the Purchaser or are being issued concurrently herewith.

    

    NOW,
      THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,
      and for other good and valuable consideration the receipt and adequacy of which
      are hereby acknowledged, the Company and the Purchaser agree as
      follows:

     

    1. Piggy
      Back Rights.
      At the
      time the Company shall determine to prepare and file with the Securities and
      Exchange Commission (the “Commission”) a registration statement relating to an
      offering for its own account or the account of others under the Securities
      Act
      of 1933, as amended, and the rules and regulations promulgated thereunder (the
      “Securities Act”), of any of its equity securities, other than (a) on Form S-4
      or Form S-8 (each as promulgated under the Securities Act) or their then
      equivalents relating to equity securities to be issued solely in connection
      with
      any acquisition of any entity or business, (b) a registration relating solely
      to
      a Commission Rule 145 transaction, (c) equity securities issuable in connection
      with stock option or other employee benefit plans, but in no event later than
      April 15, 2008, then the Company shall send to the Holder written notice of
      such
      registration statement and the Company shall include in such registration
      statement all of the shares of capital stock issuable upon conversion in full
      of
      the Note, and all shares issuable upon the exercise of warrants currently held
      by the Purchaser, as well as any shares escrowed in connection with the
      underlying transaction (the “Registerable Securities”) the Holder requests to be
      registered, subject, in the event of an underwritten offering, to customary
      cutbacks requested by the managing underwriter of all selling stockholders
      thereunder, on a pro-rata basis with any other selling stockholders. This
      registration rights agreement is subject to the company’s limitations under SEC
      Rule 415.

     

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    

    2. Right
      to Terminate Registration.
      Subject
      to the obligation in paragraph (1) herein, the Company shall have the right
      to
      terminate or withdraw any registration initiated by it under Section 1 prior
      to
      the effectiveness of such registration whether or not the Purchaser has elected
      to include Registrable Securities in such registration. The Purchaser agrees
      that, upon receipt of notice from the Company that the Company has determined
      to
      withdraw any registration statement pursuant to this subsection, such Purchaser
      will discontinue its disposition of securities pursuant to such registration
      statement and, if so directed by the Company, will deliver to the Company (at
      the Company’s expense) all copies, other than permanent file copies, then in
      such Purchaser’s possession of the prospectus covering securities which was in
      effect at the time of such notice.

    

    3. Expenses
      of Registration.
      All
      expenses, other than Selling Expenses (as defined below), incurred by the
      Company in complying with this Agreement, including, without limitation, all
      registration, qualification and filing fees, printing expenses, escrow fees,
      fees and disbursements of counsel for the Company, blue sky fees and expenses
      and the expense of any special audits incident to or required by any such
      registration (“Registration Expenses”) incurred in connection with all
      registrations pursuant to this Agreement shall be borne by the Company;
      provided, however, that in the event the Purchaser alone, but not the Company,
      initiates the request that a registration be withdrawn prior to its
      effectiveness, all Registration Expenses incurred in connection with that
      registration shall be borne by the Purchaser. All underwriting discounts,
      selling commissions and stock transfer taxes applicable to the securities
      registered by the Purchaser and, except as set forth above, all fees and
      disbursements of counsel for the Purchaser (“Selling Expenses”) relating to
      securities registered on behalf of the Purchaser shall be borne by the
      Purchaser.

    

    4. Registration
      Procedures.
      In the
      case of each registration, qualification or compliance to be effected by the
      Company pursuant to this Agreement, the Company will keep the Purchaser advised
      in writing as to the initiation of each registration, qualification and
      compliance and as to the completion thereof. The Company will:

    

    (a) use
      its
      reasonable best efforts to effect the registration and the sale of the
      Registrable Securities in accordance with the intended method of disposition
      thereof and pursuant thereto the Company will as expeditiously as
      possible;

    

    (b) prepare
      and file with the Commission a registration statement with respect to such
      Registrable Securities and use its reasonable best efforts to cause such
      registration statement to become effective (provided that before filing a
      registration statement or prospectus or any amendments or supplements thereto,
      the Company will furnish to the counsel selected by the Purchaser copies of
      all
      such documents proposed to be filed);

    

    (c) prepare
      and file with the Commission such amendments and supplements to such
      registration statement and the prospectus used in connection therewith as may
      be
      necessary to keep such registration statement effective for a period of not
      less
      than 120 days and comply with the provisions of the Securities Act with respect
      to the disposition of all securities covered by such registration statement
      during such period in accordance with the intended methods of disposition by
      the
      Purchaser set forth in such registration statement;

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

    (d) during
      the period in which the Company is required under the provisions hereof to
      keep
      a registration statement effective, furnish to the Purchaser such number of
      copies of such registration statement, each amendment and supplement thereto,
      the prospectus included in such registration statement (including each
      preliminary prospectus) and such other documents as Purchaser may reasonably
      request in order to facilitate the disposition of the Registrable Securities
      owned by Purchaser;

    

    (e) use
      its
      reasonable best efforts to register or qualify such Registrable Securities
      under
      such other securities or blue sky laws of such jurisdictions as Purchaser
      reasonably requests and do any and all other acts and things which may be
      reasonably necessary or advisable to enable Purchaser to consummate the
      disposition in such jurisdictions of the Registrable Securities owned by
      Purchaser (provided that the Company will not be required to (i) qualify
      generally to do business in any jurisdiction where it would not otherwise be
      required to qualify but for this subparagraph, (ii) subject itself to taxation
      in any such jurisdiction where it would not otherwise be subject to taxation
      but
      for this subparagraph or (iii) consent to general service of process in any
      such
      jurisdiction where it would not otherwise be subject to service of process
      but
      for this subparagraph);

    

    (f) notify
      the Purchaser any time the Company becomes aware a prospectus relating thereto
      is required to be delivered under the Securities Act, of the happening of any
      event as a result of which the prospectus included in such registration
      statement contains an untrue statement of a material fact or omits any fact
      necessary to make the statements therein not misleading, and the Company shall
      prepare a supplement or amendment to such prospectus so that, as thereafter
      delivered to the purchasers of such Registrable Securities, such prospectus
      will
      not contain an untrue statement of a material fact or omit to state any fact
      necessary to make the statements therein not misleading;

    

    (g) use
      its
      reasonable best efforts to cause all such Registrable Securities to be listed
      on
      each securities exchange on which similar securities issued by the Company
      are
      then listed and, if not so listed, to be listed on the NASD automated quotation
      system and, if listed on the NASD automated quotation system, use its reasonable
      best efforts to secure designation of all such Registrable Securities covered
      by
      such registration statement as a NASDAQ “national market system security” within
      the meaning of Rule 11Aa2-1 of the Commission or, failing that, use its best
      efforts to secure NASDAQ authorization for such Registrable
      Securities;

    

    (h) provide
      a
      transfer agent and registrar for all such Registrable Securities not later
      than
      the effective date of such registration statement;

    

    (i) enter
      into such customary agreements (including underwriting agreements in customary
      form, provided that such underwriting agreement shall be reasonably satisfactory
      to the Company) and take all such other actions as the holders of a majority
      of
      the Registrable Securities being sold or the underwriters, if any, reasonably
      request in order to expedite or facilitate the disposition of such Registrable
      Securities (including, without limitation, (i) effecting a stock split or a
      combination of shares, and (ii) not effecting any public sale or distribution
      of
      its equity securities, or any securities convertible into or exchangeable or
      exercisable for such securities, during the seven days prior to and during
      the
      180-day period beginning on the effective date of any underwritten registration
      (except as part of such underwritten registration or pursuant to registrations
      on Form S-8 or any successor form), unless the underwriters managing the
      registered public offering otherwise agree;

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    (j) upon
      receipt and execution of such confidentiality agreements as the Company may
      reasonably request from parties who are not otherwise subject to confidentiality
      obligations because of the nature of their profession (e.g., underwriters,
      attorneys and accountants), make available for inspection by the Purchaser,
      any
      underwriter participating in any disposition pursuant to such registration
      statement and any attorney, accountant or other agent retained by Purchaser
      or
      such underwriter, all financial and other records, pertinent corporate documents
      and properties of the Company, and cause the Company’s officers, directors,
      employees and independent accountants to supply all information reasonably
      requested by Purchaser or any such underwriter, attorney, accountant or agent
      in
      connection with such registration statement;

    

    (k) otherwise
      use its reasonable best efforts to comply with all applicable rules and
      regulations of the Commission; and

    

    (l) in
      the
      event of the issuance of any stop order suspending the effectiveness of a
      registration statement, or of any order suspending or preventing the use of
      any
      related prospectus or suspending the qualification of any common stock included
      in such registration statement for sale in any jurisdiction, the Company will
      use its reasonable best efforts promptly to obtain the withdrawal of such
      order.

    

    5. Indemnification.

    

    (a) The
      Company agrees to indemnify, to the extent permitted by law, each holder of
      Registrable Securities, its officers and directors and each person who controls
      such holder (within the meaning of the Securities Act) against all losses,
      claims, damages, liabilities and expenses caused by any violation or alleged
      violation by the Company of the Securities Act, the Securities Exchange Act
      of
      1934, as amended (the “Exchange Act”), any state securities law or any rule or
      regulation promulgated under the Securities Act, the Exchange Act or any state
      securities law, any untrue or alleged untrue statement of material fact
      contained in any registration statement, prospectus or preliminary prospectus
      or
      any amendment thereof or supplement thereto or any omission or alleged omission
      of a material fact required to be stated therein or necessary to make the
      statements therein not misleading, except insofar as the same are caused by
      or
      contained in any affidavits or written information supplied or withheld from
      the
      Company relating to such holder’s ownership of Registrable Securities or as
      otherwise required under the Securities Act furnished by such holder expressly
      for use in such registration statement or by such holder’s failure to deliver a
      copy of the registration statement or prospectus or any amendments or
      supplements thereto after the Company has timely furnished such holder with
      the
      number of copies of the same reasonably requested by such holder.

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    (b) In
      connection with any registration statement in which Purchaser is participating,
      Purchaser will furnish to the Company in writing such information and affidavits
      relating to such Purchaser’s ownership of Registrable Securities or as otherwise
      required under the Securities Act as the Company reasonably requests for use
      in
      connection with any such registration statement or prospectus and, to the extent
      permitted by law, will indemnify the Company, its directors and officers and
      each person who controls the Company (within the meaning of the Securities
      Act)
      against any losses, claims, damages, liabilities and expenses resulting from
      any
      untrue or alleged untrue statement of material fact contained in the
      registration statement, prospectus or preliminary prospectus or any amendment
      thereof or supplement thereto or any omission or alleged omission of a material
      fact required to be stated therein or necessary to make the statements therein
      not misleading, but only to the extent that such untrue statement or omission
      is
      contained in any information or affidavit so furnished in writing by such holder
      which was expressly provided for use in such registration statement and was
      included in such registration statement in reliance on and in conformity with
      such written information or affidavit.

    

    (c) Any
      person entitled to indemnification hereunder will (i) give prompt written notice
      to the indemnifying party of any claim with respect to which it seeks
      indemnification and (ii) unless in such indemnified party’s reasonable judgment
      a conflict of interest between such indemnified and indemnifying parties may
      exist with respect to such claim, permit such indemnifying party to assume
      the
      defense of such claim with counsel reasonably satisfactory to the indemnified
      party. If such defense is assumed or not defended because of a conflict of
      interest pursuant to clause (ii) of the preceding sentence, the indemnifying
      party will not be subject to any liability for any settlement made by the
      indemnified party without its consent (but such consent will not be unreasonably
      withheld). An indemnifying party who is not entitled to, or elects not to,
      assume the defense of a claim will not be obligated to pay the fees and expenses
      of more than one counsel for all parties indemnified by such indemnifying party
      with respect to such claim, unless in the reasonable judgment of any indemnified
      party a conflict of interest may exist between such indemnified party and any
      other of such indemnified parties with respect to such claim.

    

    (d) The
      indemnification provided for under this Agreement will remain in full force
      and
      effect regardless of any investigation made by or on behalf of the indemnified
      party or any officer, director or controlling person of such indemnified party
      and will survive the transfer of securities.

    

    (e) The
      Company also agrees to make such provisions, as are requested by any indemnified
      party, for contribution to such party in the event the Company’s indemnification
      is unavailable for any reason. The Company shall contribute to the amount paid
      or payable by such indemnified party as a result of such loss, liability, claim,
      damage, or expense in such proportion as is appropriate to reflect the relative
      fault of the indemnified party on the one hand and of the Company on the other
      in connection with the violations, statements or omissions that resulted in
      such
      loss, liability, claim, damage or expense as well as any other relevant
      equitable considerations. The relative fault of the indemnified party and of
      the
      Company shall be determined by reference to, among other things, whether the
      untrue or alleged untrue statement of a material fact or the omission to state
      a
      material fact relates to information supplied by the indemnified party or by
      the
      Company and the parties’ relative intent, knowledge, access to information, and
      opportunity to correct or prevent such statement or omission.

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    

    6. Termination
      of Registration Rights.
      The
      Company’s obligations pursuant to Section 1 shall expire upon the earlier to
      occur of the following: (a) when all Registrable Securities held by the
      Purchaser have been sold or transferred in any manner to any person or entity,
      including, but not limited to, sales pursuant to a registration statement,
      Rule
      144 sales or otherwise, (b) at such time as all Registrable Shares of the
      Purchaser can be sold in any three-month period under the Commission’s Rule 144,
      or (c) five (5) years after an Initial Public Offering.

    

    7. Stand-Off
      Agreement.
      So long
      as the Company’s obligations pursuant to Section 1 have not expired, the
      Purchaser, if requested by the Company and an underwriter of Common Stock or
      other securities of the Company, shall agree not to sell or otherwise transfer
      or dispose of any Registrable Securities or other securities of the Company
      (except for those securities being registered) held by such Purchaser for a
      specified period of time (not to exceed 180 days) following the effective date
      of a registration statement filed in connection with the Initial Public
      Offering; provided, (a) all employees, officers, directors, and greater than
      one
      percent (1%) preferred stock or Common Stock holders enter into agreements
      in
      exactly the same form, and (b) that such agreement shall be in a form reasonably
      satisfactory to the Company and such underwriter. The Company may impose
      stop-transfer instructions with respect to the Registrable Securities or other
      securities subject to the foregoing restriction until the end of the stand-off
      period.

    

    8. Miscellaneous.

    

    (a) Governing
      Law.
      This
      Agreement shall be governed in all respects by the internal laws of the State
      of
      New York.

    

    (b) Successors
      and Assigns.
      The
      provisions hereof shall inure to the benefit of, and be binding upon, the
      successors, permitted assigns, heirs, executors and administrators of the
      parties hereto.

    

    (c) Entire
      Agreement; Amendment.
      This
      Agreement, its attachments and the other documents delivered pursuant hereto
      constitute the full and entire understanding and agreement between the parties
      with regard to the subjects hereof and thereof. Except as expressly provided
      herein, neither this Agreement nor any term hereof may be amended, waived,
      discharged or terminated other than by a written instrument signed by the
      Company and the Purchaser.

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    

    (d) Counterparts.
      This
      Agreement may be executed in any number of counterparts, each of which shall
      be
      enforceable against the parties actually executing such counterparts, and all
      of
      which together shall constitute one instrument.

    

    (e) Severability.
      In the
      event that any provision of this Agreement becomes or is declared by a court
      of
      competent jurisdiction to be illegal, unenforceable or void, this Agreement
      shall continue in full force and effect without said provision; provided that
      no
      such severability shall be effective if it materially changes the economic
      benefit of this Agreement to any party.

    

    (f) Notices.
      Except
      in cases where oral or other notice is permitted by this Agreement, all notices,
      requests, demands and other communications hereunder shall be in writing and
      shall be deemed to have been given (i) when hand delivered, including delivery
      by messenger or courier service (or if delivery is refused, at the time of
      refusal), to the address set forth below, (ii) when received or refused as
      evidenced by the postal receipt if sent by United States mail as Certified
      Mail,
      Return Receipt Requested, with proper postage prepaid, addressed as set forth
      below or (iii) when received as evidenced by the transmission report of the
      telefax machine of the transmitting party acknowledging a good transmission
      if
      sent by telefax to the number set forth below:

    

    a.           
       If
      to
      Purchaser:

     

     

     

    
      
        

      

    

    JANE
      PETRI

    

    c/o
      THELEN
      REID BROWN RAYSMAN & STEINER, LLP

    Attn:
      Mark Canizio

    900
      THIRD
      AVENUE

    NEW
      YORK,
      NEW YORK  10022

    

    b.            
      If
      to the
      Company:

    

    bioMETRX,
      INC.

    500
      North
      Broadway

    Suite
      204

    Jericho,
      NY 11753

    

    Any
      of
      the parties may change its mailing address or telecopy number, by giving notice
      to the other party pursuant to this Subsection.

     

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    

    (g) Titles
      and Subtitles.
      The
      titles and subtitles used in this Agreement are used for convenience only and
      are not considered in construing or interpreting this Agreement.

    

    

    IN
      WITNESS WHEREOF, the parties below have executed this Agreement all as of the
      date first written above.

    

    PURCHASER:

    

    ________________________________

     

    By:
      
      
        

      

    

    Name:
      

    Title:
      

     

    COMPANY:    

    bioMETRX,
      INC.

    By:
      

    
      

    

    Name:
      Mark Basile

    Title:
      Chief Executive Officer

     

    
      
         

      

      
        8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]